# ClinicalTrials.gov record NCT03746041

> PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct03746041-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03746041-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03746041-abaloparatide-v1.json
- Content SHA-256: `1606094257a7dafb0334dc884a011cf949616fb3a287c2ab76544e873c7f570e`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03746041 ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`](#source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e))

## Sources

<a id="source-ctg-observation-nct03746041-2023-01-23-cddca69ce77e"></a>
- **ClinicalTrials.gov record NCT03746041 · retained source version 2023-01-23:cddca69ce77ee5554f5751c0045b9c727c01f584547d611d15e22dfed606620c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03746041) (`ctg-observation-nct03746041-2023-01-23-cddca69ce77e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03746041." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03746041-abaloparatide-v1.json SHA-256: 1606094257a7dafb0334dc884a011cf949616fb3a287c2ab76544e873c7f570e.